hypertension

News

The race to market is on with Mineralys, as AstraZeneca showcases data for aldosterone synthase inhibitor baxdrostat in uncontrolled hypertension.

News

Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.

News

George Medicines' Widaplik can address key challenges in current hypertension treatment, according to the UK drugmaker's CEO.

News

Mineralys looks odds on to become the first drug developer to bring an aldosterone synthase inhibitor to market for uncontrolled hypertension.

News

Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.

News

Closed Loop Medicine's smartphone app for blood pressure monitoring has shown proof-of-concept in the Cure-19 study.